Found: 148
Select item for more details and to access through your institution.
Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 10, p. 2841, doi. 10.1007/s13555-024-01261-6
- By:
- Publication type:
- Article
Impact of Disease Factors of Patients with Psoriasis and Psoriatic Arthritis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 10, p. 2805, doi. 10.1007/s13555-024-01258-1
- By:
- Publication type:
- Article
Impact of Disease Burden of Patients with Psoriasis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 10, p. 2787, doi. 10.1007/s13555-024-01257-2
- By:
- Publication type:
- Article
Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis—A pooled analysis of trial data.
- Published in:
- Pediatric Dermatology, 2022, v. 39, n. 2, p. 187, doi. 10.1111/pde.14909
- By:
- Publication type:
- Article
Developing drugs for treatment of atopic dermatitis in children (≥3 months to <18 years of age): Draft guidance for industry.
- Published in:
- Pediatric Dermatology, 2018, v. 35, n. 3, p. 303, doi. 10.1111/pde.13452
- By:
- Publication type:
- Article
Human papillomavirus DNA in the dermis of condyloma acuminatum.
- Published in:
- Journal of Cutaneous Pathology, 1993, v. 20, n. 5, p. 447, doi. 10.1111/j.1600-0560.1993.tb00669.x
- By:
- Publication type:
- Article
Deucravacitinib: A Novel TYK2 Inhibitor for the Treatment of Moderate-to-Severe Psoriasis.
- Published in:
- Journal of Psoriasis & Psoriatic Arthritis, 2023, v. 8, n. 4, p. 156, doi. 10.1177/24755303231201336
- By:
- Publication type:
- Article
Psoriasis Involving Special Areas is Associated with Worse Quality of Life, Depression, and Limitations in the Ability to Participate in Social Roles and Activities.
- Published in:
- Journal of Psoriasis & Psoriatic Arthritis, 2023, v. 8, n. 3, p. 100, doi. 10.1177/24755303231160683
- By:
- Publication type:
- Article
Resident Memory T Cells in Psoriasis: Key to a Cure?
- Published in:
- 2022
- By:
- Publication type:
- Editorial
Extending Maintenance Dosing Intervals for Guselkumab in the Treatment of Patients With Psoriasis.
- Published in:
- 2024
- By:
- Publication type:
- Opinion
Cendakimab in Patients With Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.
- Published in:
- JAMA Dermatology, 2024, v. 160, n. 8, p. 856, doi. 10.1001/jamadermatol.2024.2131
- By:
- Publication type:
- Article
Reanalysis Following Removal of Participants From 1 Site in Multicenter Trial of Upadacitinib vs Dupilumab for Atopic Dermatitis.
- Published in:
- 2024
- By:
- Publication type:
- Letter
The Best Psoriasis Medications Emerge.
- Published in:
- JAMA Dermatology, 2024, v. 160, n. 1, p. 99, doi. 10.1001/jamadermatol.2023.4445
- By:
- Publication type:
- Article
Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial.
- Published in:
- JAMA Dermatology, 2023, v. 159, n. 6, p. 596, doi. 10.1001/jamadermatol.2023.0627
- By:
- Publication type:
- Article
Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).
- Published in:
- JAMA Dermatology, 2023, v. 159, n. 2, p. 182, doi. 10.1001/jamadermatol.2022.5534
- By:
- Publication type:
- Article
Association of Apremilast With Vascular Inflammation and Cardiometabolic Function in Patients With Psoriasis: The VIP-A Phase 4, Open-label, Nonrandomized Clinical Trial.
- Published in:
- JAMA Dermatology, 2022, v. 158, n. 12, p. 1394, doi. 10.1001/jamadermatol.2022.3862
- By:
- Publication type:
- Article
Outcomes of COVID-19 and Vaccination in Patients With Moderate to Severe Atopic Dermatitis Treated With Tralokinumab.
- Published in:
- JAMA Dermatology, 2022, v. 158, n. 11, p. 1327, doi. 10.1001/jamadermatol.2022.3488
- By:
- Publication type:
- Article
Clinical and Serological Characterization of Orf-Induced Immunobullous Disease.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Predicting Clinical Responses to Ustekinumab: Progress Toward a Future of Personalized Medicine.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies.
- Published in:
- BioDrugs, 2022, v. 36, n. 5, p. 625, doi. 10.1007/s40259-022-00546-6
- By:
- Publication type:
- Article
Sequelae of World War II: An Outbreak of Chronic Cutaneous Nontuberculous Mycobacterial Infection among Satowanese Islanders.
- Published in:
- Clinical Infectious Diseases, 2009, v. 48, n. 11, p. 1541, doi. 10.1086/598928
- By:
- Publication type:
- Article
Human Herpesvirus 8 Infection Occurs following Adolescence in the United States.
- Published in:
- Journal of Infectious Diseases, 1997, v. 176, n. 3, p. 771
- By:
- Publication type:
- Article
Implications for Biologic Therapy: Staphylococcus aureus Decolonization of Individuals With a History of Recurrent Skin and Soft-Tissue Infections.
- Published in:
- JAMA Dermatology, 2013, v. 149, n. 8, p. 986, doi. 10.1001/jamadermatol.2013.4405
- By:
- Publication type:
- Article
WIDESPREAD PRIMARY CUTANEOUS INFECTION WITH <em> MYCOBACTERIUM FORTUITUM</em>.
- Published in:
- International Journal of Dermatology, 1993, v. 32, n. 7, p. 512, doi. 10.1111/j.1365-4362.1993.tb02836.x
- By:
- Publication type:
- Article
PORPHYRIA CUTANEA TARDA AND HUMAN IMMUNODEFICIENCY VIRUS INFECTION.
- Published in:
- 1992
- By:
- Publication type:
- Report
CUTANEOUS CRYPTOCOCCOSIS MIMICKING KAPOSI'S SARCOMA AS THE INITIAL MANIFESTATION OF DISSEMINATED DISEASE.
- Published in:
- International Journal of Dermatology, 1992, v. 31, n. 4, p. 279, doi. 10.1111/j.1365-4362.1992.tb03572.x
- By:
- Publication type:
- Article
Low levels of productive HIV infection in Langerhans cell-like dendritic cells differentiated in the presence of TGF-β1 and increased viral replication with CD40 ligand-induced maturation.
- Published in:
- European Journal of Immunology, 2001, v. 31, n. 2, p. 360, doi. 10.1002/1521-4141(200102)31:2<360::AID-IMMU360>3.0.CO;2-X
- By:
- Publication type:
- Article
Fractalkine, a CX3C chemokine, is expressed by dendritic cells and is up-regulated upon dendritic cell maturation.
- Published in:
- European Journal of Immunology, 1999, v. 29, n. 8, p. 2551, doi. 10.1002/(SICI)1521-4141(199908)29:08<2551::AID-IMMU2551>3.0.CO;2-T
- By:
- Publication type:
- Article
Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2).
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 8, p. 1543, doi. 10.1111/jdv.19925
- By:
- Publication type:
- Article
Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 1, p. 137, doi. 10.1111/jdv.18571
- By:
- Publication type:
- Article
Pathophysiology of psoriasis: Recent advances on IL-23 and Th17 cytokines.
- Published in:
- Current Rheumatology Reports, 2007, v. 9, n. 6, p. 461, doi. 10.1007/s11926-007-0075-1
- By:
- Publication type:
- Article
Clinically relevant improvements in adults and adolescents with atopic dermatitis who did not achieve Investigator's Global Assessment treatment success following 8 weeks of ruxolitinib cream monotherapy.
- Published in:
- Journal of Dermatology, 2023, v. 50, n. 12, p. 1523, doi. 10.1111/1346-8138.16975
- By:
- Publication type:
- Article
The Effect of Lebrikizumab on Inflammatory Biomarkers in Patients with Asthma.
- Published in:
- touchREVIEWS in Respiratory & Pulmonary Diseases, 2023, v. 8, n. 1, p. 2, doi. 10.17925/USRPD.2023.8.1.2
- By:
- Publication type:
- Article
Bimekizumab for the Treatment of Psoriasis.
- Published in:
- Drugs, 2021, v. 81, n. 15, p. 1751, doi. 10.1007/s40265-021-01612-z
- By:
- Publication type:
- Article
Authors’ Reply to Pires et al.: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”.
- Published in:
- Drugs, 2018, v. 78, n. 8, p. 853, doi. 10.1007/s40265-018-0919-1
- By:
- Publication type:
- Article
HIV-Dendritic Cell Interactions Promote Efficient Viral Infection of T Cells.
- Published in:
- Journal of Biomedical Science, 1998, v. 5, n. 4, p. 253, doi. 10.1007/BF02255856
- By:
- Publication type:
- Article
Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review.
- Published in:
- Advances in Therapy, 2023, v. 40, n. 8, p. 3410, doi. 10.1007/s12325-023-02568-0
- By:
- Publication type:
- Article
No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab.
- Published in:
- Advances in Therapy, 2023, v. 40, n. 1, p. 367, doi. 10.1007/s12325-022-02322-y
- By:
- Publication type:
- Article
Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan<sup>®</sup> Databases.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 7, p. 3214, doi. 10.1007/s12325-022-02155-9
- By:
- Publication type:
- Article
722 - Efficacy of povorcitinib for the treatment of vitiligo by patient demographics and baseline clinical characteristics: week 52 subgroup analysis from a randomized, placebo-controlled, phase 2b clinical trial.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.095
- By:
- Publication type:
- Article
721 - Efficacy and safety of povorcitinib for extensive vitiligo: 52-week results from a double-blinded, placebo-controlled, dose-ranging phase 2b study.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.094
- By:
- Publication type:
- Article
698 - Impact of amlitelimab (an anti-OX40 ligand antibody) on clinical outcome assessments for atopic dermatitis: results from the 52-week STREAM-AD phase 2b study in adults with moderate-to-severe atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.072
- By:
- Publication type:
- Article
693 - Efficacy and safety of orismilast, a potent PDE4B/D inhibitor, in adults with moderate-to-severe atopic dermatitis: a phase 2b randomized, double-blind, placebo-controlled clinical trial (ADESOS).
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.067
- By:
- Publication type:
- Article
661 - Efficacy and safety of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis (AD): a phase 2b trial (STREAM-AD).
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.039
- By:
- Publication type:
- Article